HannaKSanoffMD
Oncology • Chapel Hill, NCGastrointestinal Cancer
Associate Professor of Medicine, University of North Carolina at Chapel Hill
Dr. Sanoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
170 Manning Dr Cb 7305
Chapel Hill, NC 27599
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2003 - 2006- University of North Carolina HospitalsResidency, Internal Medicine, 2000 - 2003
Perelman School of Medicine at the University of PennsylvaniaClass of 2000
University of North CarolinaMPH
Certifications & Licensure
NC State Medical License 2000 - 2025
VA State Medical License 2009 - 2012- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors Start of enrollment: 2013 Jun 01
- Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer Start of enrollment: 2014 May 01
- Physical Activity Intervention for Older Patients During Chemotherapy for Colorectal Cancer Start of enrollment: 2014 Jun 01
Publications & Presentations
PubMed
- PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer.Ashwin Somasundaram, Hanna K Sanoff
Cancer Cell. 2024-09-09 - A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.Hanna K Sanoff, Allison M Deal, Jai Patel, Jonathan D Sorah, Jacquelyne Gaddy
The Oncologist. 2024-09-06 - Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.Jonathan D Sorah, Allison M Deal, Sophia I Stein, Mattias Jonsson, Federico Innocenti
The Oncologist. 2024-09-06
Journal Articles
- Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients with Advanced CancerAndrea C Enzinger, Hanna Sanoff, Deborah Schrag, JAMA Oncology
Other
- Managing Grief, Loss, and Connection in Oncology—What COVID-19 Has TakenHanna Sanoff, MD, JAMA Oncology
https://www.doximity.com/articles/0ffd1782-e5f4-4ede-91e0-1564bccde546
UpToDate, Wolters Kluwer Health - 2013-02-13 - Telemedicine for Cancer Care in the Time of COVID-19Hanna Sanoff, MD, JAMA Oncology
https://www.doximity.com/articles/9ec36519-1f99-4287-87f3-a0473fbf5672
UpToDate, Wolters Kluwer Health - 2013-04-09
Authored Content
- Managing Grief, Loss, and Connection in Oncology—What COVID-19 Has TakenJuly 2020
- Managing Grief, Loss, and Connection in Oncology—What COVID-19 Has TakenJuly 2020
- Telemedicine for Cancer Care in the Time of COVID-19July 2020
Press Mentions
FDA’s ODAC: Risks Outweigh Benefits for Checkpoint Inhibitors in Some CancersSeptember 30th, 2024- Carolina Cancer Experts Available for InterviewsMay 19th, 2023
- Scientists Intrigued by Treatment That Put Every Single Patient's Cancer into RemissionAugust 11th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
